Skip to content
FY'25FY'24FY'23FY'22
Profitability
Operating margin105.1%-10.1pp115.1%-17.9pp133.1%-54.6pp187.6%-20.5pp
Net margin126.8%+0.7pp126.2%-2.2pp128.4%-34.5pp162.8%-32.7pp
Returns
Return on equity61.4%-3.6pp65%-7.0pp72%-58.2pp130.2%-59.6pp
Return on invested capital45%-10.1pp55.1%-13.9pp69%-64.6pp133.6%-41.1pp
Efficiency
Asset turnover1.5×-0.1×1.6×-0.1×1.7×-0.6×2.3×-0.4×
Liquidity
Current ratio17.7×-3.0×20.7×-1.1×21.8×+1.5×20.3×+6.3×
Leverage
Debt-to-equity0.4×0.0×0.4×-0.1×0.4×-0.1×0.5×-0.2×
Net debt / EBITDA0.1×-0.4×0.5×+0.4×+0.4×-0.4×-0.6×
Per Share
Book value per share$1,116.56+13.2%$986.32+14.0%$865.02+15.8%$747.30+32.6%
Valuation
Market capitalization$266.44B-34.9%$408.97B+18.4%$345.41B+17.3%$294.4B+20.7%
Price / earnings59.1×-36.2×95.3×+10.9×84.4×+31.3×53.1×+13.0×
Price / sales18.7×-11.3×30×+3.1×27×+5.9×21.1×+1.7×
Price / book8.8×-5.6×14.4×+0.4×14×+0.1×13.9×-1.7×
EV / EBITDA62.9×-30.8×93.7×+19.4×74.4×+30.7×43.7×+7.0×
Dividend yield1.4%0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Regeneron Pharmaceuticals's profit margins?
Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.
Where do Regeneron Pharmaceuticals's ratios come from?
Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.